CVS Health outperformed as investor focus shifts to improving operational execution and payer margin outlook in Q2 2026.
CVS Health Corporation (CVS) gained in Q2 2026 as the company’s improving execution and stronger payer margin outlook attracted investor attention. The stock was highlighted in Victory Capital’s RS Large Cap Value Strategy investor letter, which noted relative outperformance despite broader market challenges.
The S&P 500 rose 15% in the quarter, while the Russell 1000 Value returned 13.9%, with market leadership broadening beyond mega-cap tech. Information Technology led sector gains at 80.63%, while Energy declined 13.77%. The RS Large Cap Value Strategy underperformed due to unfavorable stock selection in Technology and Industrials.
Victory Capital emphasized a focus on valuation discipline and financially strong companies trading below intrinsic value. CVS was identified as a top holding, reflecting confidence in its turnaround potential.